2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2384

Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 2385

High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment
Abstract Number: 2386

The Risk Factors of Newly Developing/Worsening Pulmonary Abnormalities in Rheumatoid Arthritis
Abstract Number: 2387

Prevalence of Hepatitis C Virus Infection in Egyptian Patients with Rheumatoid Arthritis
Abstract Number: 2388

Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities
Abstract Number: 2389

Joint Surgery in Rheumatoid Arthritis 1980-2013: A Population-Based Study to Identify Risk Factors and Time Trends in Incidence
Abstract Number: 2390

Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort
Abstract Number: 2391

Incidence of Infections in Early Arthritis
Abstract Number: 2392

Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2393

Evaluation of Live Zoster Vaccine in a Subset of Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, and Adalimumab with Methotrexate: Results from a Phase 3b/4 Randomized Trial
Abstract Number: 2394

Differential Effect of Corticosteroids and Biological Dmards on Five-Year Radiographic Progression in Rheumatoid Arthritis: Results from a Weighted Cumulative Exposure Model Developed on the Espoir Cohort
Abstract Number: 2395

Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements
Abstract Number: 2396

Safety and Humoral and Cell-Mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis
Abstract Number: 2397

Bilateral Femoral DXA Scan in Patients with Rheumatoid Arthritis
Abstract Number: 2398

A Population-Based Cohort Study of Chronic Obstructive Pulmonary Disease Among Patients with Rheumatoid Arthritis: Comorbidity and Mortality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].